Trametinib is an FDA-approved MEK1/2 inhibitor that is used to treat cancers caused by hyperactive RAS/MAPK signaling, such as melanoma, non–small cell lung cancer, and anaplastic thyroid cancer (22–24). This evidence concerns the gene MAP2K1 and thyroid gland undifferentiated (anaplastic) carcinoma.